Oculis Holding AG (OCS) Treasury Shares (2021 - 2026)
Oculis Holding AG (OCS) recorded quarterly Treasury Shares of -$21709.1 in Q1 2026, down 147.87% quarter-over-quarter from -$8758.2 in Q4 2025, and up 44.23% on a YoY basis from -$15051.3 in Q1 2025.
Oculis Holding AG (OCS) Treasury Shares (2021 - 2026) Analysis & Trends
Oculis Holding AG's Treasury Shares history runs 5 years deep, the most recent figure standing at -$21709.1 for Q1 2026.
- In Q1 2026, Treasury Shares rose 44.23% year-over-year to -$21709.1; the TTM figure through Mar 2026 stood at -$21709.1 (up 44.23% YoY), while the FY2025 annual figure was -$8758.2, up 23.28% from the prior year.
- Treasury Shares was -$21709.1 for Q1 2026 at Oculis Holding AG, down from -$8758.2 in the prior quarter.
- In the past five years, Treasury Shares ranged from a high of -$1038.0 in Q4 2022 to a low of -$43753.8 in Q3 2025.
- Historically, Treasury Shares has averaged -$21164.4 across 4 years, with a median of -$11542.1 in 2024.
- The sharpest annual moves came in 2025 and 2026: Treasury Shares tumbled 282.32% in 2025, then surged 44.23% in 2026.
- A 4-year view of Treasury Shares shows it stood at -$1038.0 in 2022, then tumbled by 999.71% to -$11415.2 in 2024, then advanced by 23.28% to -$8758.2 in 2025, then plunged by 147.87% to -$21709.1 in 2026.
- The last three Treasury Shares figures came in at -$21709.1 (Q1 2026), -$8758.2 (Q4 2025), and -$43753.8 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 1.48 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 700,000.00 |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Oculis Holding AG | 8.23 Bn | 7.92 Bn | - | -21,709.08 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21,709.08 |
| Mar 31, 2026 | -21,709.08 |
| Dec 31, 2025 | -8,758.19 |
| Dec 31, 2025 | -8,758.19 |
| Sep 30, 2025 | -43,753.83 |
| Sep 30, 2025 | -43,753.83 |
| Jun 30, 2025 | -42,276.16 |
| Jun 30, 2025 | -42,276.16 |
| Mar 31, 2025 | -38,928.77 |
| Mar 31, 2025 | -38,928.77 |
| Dec 31, 2024 | -11,415.22 |
| Dec 31, 2024 | -11,415.22 |
| Sep 30, 2024 | -11,542.07 |
| Sep 30, 2024 | -11,542.07 |
| Jun 30, 2024 | -11,057.93 |
| Jun 30, 2024 | -11,057.93 |
| Dec 31, 2022 | -1,038.02 |
| Dec 31, 2022 | -1,038.02 |
| Dec 31, 2021 | 108,450.21 |
| Dec 31, 2021 | 108,450.21 |